Michael Trotter, MD
Urology · Austin, TXNPI 1992779599
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $430,024 of the $590,284 with a category attached, or 72.9%. 27 manufacturers reported payments, led by Teleflex LLC at 54.2% of the total. Reporting peaked in 2019 at $150,769 and has fallen 98.8% since, to $1,745 in 2025. Among urology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 595 payments — averaging $992.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teleflex LLC$320K
- Neotract Inc.$254K
- Olympus America Inc.$14K
- Boston Scientific$877
- AbbVie$320
- Astellas Pharma US Inc$187
- plus $911 from 21 others
Across 32 payments — averaging $9421.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Neotract Inc.$168K
- Laborie Medical Technologies Corp.$114K
- Teleflex LLC$20K
What the payments were for
- Consulting fees$126,34721%
- Speaking & faculty fees$430,02473%
- Travel & lodging$4,2811%
- Food & beverage$15,6273%
- Education$14,0062%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teleflex LLC | 277 | $319,761 |
| Neotract Inc. | 226 | $254,022 |
| Olympus America Inc. | 15 | $14,207 |
| Boston Scientific | 26 | $877 |
| AbbVie(2 entities) | 14 | $320 |
| Astellas Pharma US Inc | 3 | $187 |
| Procept Biorobotics Corporation | 7 | $180 |
| Palette Life Sciences, Inc. | 1 | $109 |
| Biotissue Holdings Inc. | 1 | $71 |
| Ferring Pharmaceuticals Inc. | 3 | $70 |
| Axonics, Inc. | 2 | $62 |
| Endo USA, Inc. | 2 | $54 |
| Biogen | 1 | $53 |
| Sumitomo Pharma America, Inc. | 2 | $50 |
| Accord Healthcare, Inc. | 2 | $38 |
| Antares Pharma, Inc. | 2 | $28 |
| Telix Pharmaceuticals | 1 | $23 |
| 180 Medical, Inc. | 1 | $22 |
| Tolmar, Inc. | 1 | $21 |
| Progenics Pharmaceuticals, Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $18 |
| Myriad Genetic Laboratories, Inc. | 1 | $17 |
| Pfizer | 1 | $17 |
| Mission Pharmacal Company | 1 | $16 |
| Stimwave Technologies Incorporated | 1 | $14 |
| Endo Pharmaceuticals Inc. | 1 | $14 |
| Laborie Medical Technologies Corp. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift$358,593
- UroLift System$208,923
- HD CAMERA HEAD$13,827
- CYSTO-NEPHRO VIDEOSCOPE$13,827
- UroLift ATC System$800
- SpaceOAR VUE System - 10mL$229
How this compares
$590,284 in reported general payments places this provider in the 95th percentile of 878 urology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 18 | $252,790 |
| GemtesaVibegron | 13 | $16,116 |
| Tamsulosin Hcl | 231 | $3,040 |
| Dutasteride | 47 | $1,824 |
| Testosterone Cypionate | 22 | $1,514 |
| Silodosin | 13 | $1,235 |
| NitrofurantoinNitrofurantoin Macrocrystal | 20 | $934 |
| Estradiol | 11 | $859 |
| Finasteride | 53 | $792 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 25 | $514 |
| CefuroximeCefuroxime Axetil | 31 | $416 |
| Cephalexin | 14 | $308 |
| Ciprofloxacin Hcl | 41 | $255 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 13 | $151 |
| Bicalutamide | 13 | $147 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $187 | $252,79018 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $50 | $16,11613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 878 urology providers in Texas.
Other urology in Austin
- Varun SundaramAustin$400K
- Elizabeth MobleyAustin$254K
- Parviz KavoussiAustin$251K
- Peter RuffAustin$168K
- Bryan KansasAustin$120K
- Aaron LavianaAustin$78K
- Kyle KeyesAustin$58K
- Andrew von EschenbachMontgomery$3.2M
- Brian MazzarellaLakeway$1.2M
- Arun RaiHouston$920K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.